46.5300.26% ( +0.120 )
Closed: Nov 20, 16:00:00 (EDT)Financials
Q3 FY2026 EarningsQ3 FY26 results beat consensus on earnings per share, with GAAP EPS at -$0.36 vs. -$0.46 expected, primarily driven by higher-than-anticipated non-operating income of $8.3M. R&D expenses increased to $28.0M as the company prepares to initiate the Phase 3 ENABLE-2 trial by year-end 2026. The balance sheet remains exceptionally strong with $884.4M in cash, extending the projected runway into 2030, well beyond current clinical milestones.
Financial report interval: 2026.06.30 - 2026.09.30
Overview: Enliven Therapeutics(ELVN) the EBIT is -36.05 M (-43.63%), Beat estimate;the EPS is -0.36 (-12.5%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.04B43.63%
-0.04B58.79%
+0.00B15.16%
EPSExceed expectations
-0.3612.50%
-0.438537.04%
+0.078524.54%
Upcoming earnings report - FY2026 Annual Earning Release
Available dateMar 3, 2027
Estimate Revenue0
Estimate EBIT-145.86M
Estimate EPS-1.7218
Revenue
ActualEstimateUnit: USD
Quarterly
EBIT
ActualEstimateUnit: USD
Quarterly
Net income
ActualEstimateUnit: USD
Quarterly
EPS
ActualEstimateUnit: USD
Quarterly
